| Eric M. Reiman | |
|---|---|
| Photo placeholder | |
| Affiliations | Banner Alzheimer's Institute University of Arizona |
| Country | USA |
| H-index | 180 |
| ORCID | 0000-0001-5012-1883 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Biomarkers, Neuroimaging, Prevention |
Eric M. Reiman is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Eric M. Reiman is a pioneering neuroscientist and psychiatrist whose work has fundamentally advanced our understanding of Alzheimer's disease biomarkers, brain imaging, and prevention strategies. As Executive Director of the Banner Alzheimer's Institute and Professor of Psychiatry at the University of Arizona, Reiman has led transformative research programs in Alzheimer's disease detection and prevention[1].
With an h-index of 180 and over 600 peer-reviewed publications, Reiman is recognized worldwide for his contributions to neuroimaging biomarkers, early detection, and the design of Alzheimer's prevention trials[2].
Reiman's neuroimaging work has been groundbreaking:
Reiman founded and led the Alzheimer's Prevention Initiative (API), a landmark prevention trial program:
His biomarker research includes:
APE3 Mutation Carriers: Characterized the largest known family with autosomal dominant Alzheimer's disease (the Colombian PSEN1 E280A kindred)[4]
Preclinical AD Biomarkers: Established biomarker changes that occur decades before clinical symptoms in Alzheimer's disease[5]
Brain Reserve Hypothesis: Contributed to understanding of cognitive reserve and brain resilience to AD pathology[6]
Treatment Response Biomarkers: Identified neuroimaging markers predictive of treatment response in AD clinical trials
Brain imaging in Alzheimer's disease. Nat Rev Neurol, 2017.
Alzheimer's disease: Are we close to effective prevention?. Alzheimer's & Dementia, 2016.
Preclinical AD: Amyloid, tau, and neurodegeneration. Neurobiol Aging, 2012.
The Colombian autosomal dominant AD kindred. Alzheimer's & Dementia, 2014.
APOE and brain imaging in AD. Neurobiol Aging, 2007.
Recent work includes:
The study of Eric M. Reiman has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reiman EM, et al. (2020). "The Alzheimer's Prevention Initiative Composite Cognitive Test." Alzheimer's & Dementia. DOI
Reiman EM, et al. (2012). "Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease." Lancet Neurol. DOI
Reiman EM, et al. (1996). "Preclinical evidence of Alzheimer's disease in persons with the APOE ε4 allele." JAMA. DOI
Reiman EM, et al. (2011). "Alzheimer's Prevention Initiative: A proposal to evaluate presymptomatic interventions." Neurobiology of Aging. DOI
Jack CR, et al. (2013). "Tracking pathophysiological processes in Alzheimer's disease." Lancet Neurol. DOI
Reiman EM, et al. (2005). "APOE affects the rate of decline in Alzheimer's disease." JAMA. DOI
Page updated: 2026-03-05